BTK and neoplasm: Preclinical evidence of persistent mTORC1-driven tumor viability (62% vs vehicle) (12) raises concerns that subtherapeutic BTK inhibition may paradoxically accelerate adaptive resistance via PI3K/AKT pathway hyperactivation, necessitating longitudinal clonal dynamics monitoring in dose-de-escalated regimens.